Pursuant to the provisions of Regulation 33 and other applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (''SEBI LODR''), we wish to inform ....
Awaiting price reaction for this filing.
ADS Diagnostic Limited reported a sharp decline in its FY25 performance with revenue from operations falling to Rs 1,599.96 lacs from Rs 2,396.20 lacs in FY24, a drop of about 33%. Net profit for the year also nearly halved to Rs 80.50 lacs (vs Rs 185.00 lacs in FY24), while EPS came in at Rs 3.67 vs Rs 8.44 earlier. Even for the March 2025 quarter, revenue dropped to Rs 334.48 lacs from Rs 590.98 lacs and profit after tax fell to Rs 7.10 lacs from Rs 33.18 lacs. The board has recommended a 6% dividend (Rs 0.60 per share on face value of Rs 10) subject to shareholder approval. Operating cash flow also weakened to Rs 77.73 lacs from Rs 198.73 lacs, and the company saw a notable build-up in inventory (Rs 898.99 lacs vs Rs 615.70 lacs) and trade payables. The auditor V.N. Purohit & Co. issued an unmodified opinion on the results.
This is a clearly negative result for shareholders with revenue and profits both falling sharply year-on-year, indicating business pressure on the company's core trading and servicing operations. The modest 6% dividend offers some return, but the weak operating cash flow and shrinking margins suggest limited near-term catalysts for the stock price.